<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sickle cell disease: Obstetric considerations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sickle cell disease: Obstetric considerations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sickle cell disease: Obstetric considerations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andra H James, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel A Oppong, MD, FWACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aaron B Caughey, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R DeBaun, MD, MPH</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most pregnancies in individuals with sickle cell disease (SCD) result in live birth of healthy neonates. </p><p>However, there are maternal and fetal risks of which clinicians and patients need to be aware. These risks are due, at least in part, to the metabolic demands, hypercoagulable state, endothelial dysfunction, severe anemia, and increased vaso-occlusive episodes associated with pregnancy in individuals with SCD. Access to a multidisciplinary care team knowledgeable about SCD and obstetric management of complicated pregnancies can significantly decrease morbidity and mortality in both high-income and low-income settings.</p><p>This topic will discuss the management of pregnancy-related issues in individuals with SCD. Other considerations for individuals with SCD are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations – (See  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Pathophysiology – (See  <a class="medical medical_review" href="/z/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis – (See  <a class="medical medical_review" href="/z/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Management – (See  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p></p><p class="headingAnchor" id="H1011610"><span class="h1">BEFORE CONCEPTION</span></p><p class="headingAnchor" id="H2180693954"><span class="h2">Counseling prior to pregnancy</span><span class="headingEndMark"> — </span>Individuals with SCD are at increased risk of obstetric and fetal complications, as well as medical complications of SCD. (See <a class="local">'Maternal risks'</a> below and <a class="local">'Pediatric outcomes'</a> below.)</p><p>However, these complications can be significantly decreased by early management by a multidisciplinary care team [<a href="#rid1">1-3</a>]. Despite these increased risks, the majority of individuals with SCD who become pregnant have not had adequate or effective preconception counseling [<a href="#rid4">4,5</a>].</p><p>Assessment and counseling of individuals with SCD prior to conception should include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Information about the hemoglobin status of their partner and the likelihood of a newborn with SCD, the prognosis of an affected offspring, the option to speak with a genetic counselor, and discussion of available reproductive options. (See <a class="local">'Likelihood of SCD in offspring and reproductive options'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Information about the risk pregnancy poses to the mother's health, based on pre-pregnancy health assessment. (See <a class="local">'Baseline health assessment and risks to the patient'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discussion of medication management, especially <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>. (See <a class="local">'Vaccines and medication management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discussion of possible cord blood banking for a relative with SCD. (See <a class="local">'Cord blood'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate vaccines and other routine preconception care. (See  <a class="medical medical_review" href="/z/d/html/448.html" rel="external">"The preconception office visit"</a>.)</p><p></p><p class="headingAnchor" id="H3132505482"><span class="h2">Likelihood of SCD in offspring and reproductive options</span><span class="headingEndMark"> — </span>The likelihood of SCD in offspring depends on the genotypes of both parents. Thus, it is important to verify the mother's diagnosis (homozygous Hb S versus Hb SC disease versus sickle-beta thalassemia), and to test the father for SCD and other hemoglobinopathies, as noted in 2014 guidelines [<a href="#rid6">6,7</a>]. </p><p>Couples who are planning pregnancy when the mother has SCD should have extensive counselling about the mode of inheritance, associated risk to the fetus, and common complications to mother and fetus at each stage of the pregnancy. Culturally-sensitive and non-directive support for preconception genetic testing of the father is recommended [<a href="#rid8">8</a>]. </p><p>If the father tests positive for any hemoglobinopathy, referral to a genetic counselor is useful to discuss the type and risk of inherited disease in offspring, and the variability of phenotype. This is also a good time to discuss the range of pregnancy options, as appropriate:</p><p class="bulletIndent1"><span class="glyph">●</span>If <strong>both parents are homozygous</strong> for Hb S, the risk of SCD in offspring is <strong>100 percent</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <strong>one parent is homozygous</strong> for Hb S and the other is heterozygous for Hb S (sickle cell trait), the risk of SCD in offspring is <strong>50 percent</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <strong>both parents are heterozygous</strong> for Hb S (sickle cell trait), the risk of SCD in offspring is <strong>25 percent</strong>  (<a class="graphic graphic_figure graphicRef123050" href="/z/d/graphic/123050.html" rel="external">figure 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <strong>one</strong> <strong>parent has no hemoglobinopathy</strong> variants, the risk of SCD in offspring is <strong>zero</strong>, regardless of the other parent's status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other variants</strong> (Hb C, beta thalassemia) of either parent will impact the risk of SCD or other hemoglobinopathy in offspring.</p><p></p><p>The opportunity for discussion with a genetic counselor should be made available.</p><p>Reproductive options to avoid having an offspring with SCD include:</p><p class="bulletIndent1"><span class="glyph">●</span>Preimplantation genetic testing (PGT) to select unaffected embryos for implantation; PGT requires conception by in vitro fertilization (IVF). (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a> and  <a class="medical medical_review" href="/z/d/html/134342.html" rel="external">"In vitro fertilization: Procedure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sperm donation or oocyte donation from a donor without a hemoglobinopathy. (See  <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">"Donor insemination"</a> and  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions", section on 'Oocyte donation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adoption. (See  <a class="medical medical_review" href="/z/d/html/2854.html" rel="external">"Adoption"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late first or early second trimester fetal diagnostic testing, with pregnancy termination if the fetus is affected. (See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination"</a>.)</p><p></p><p>Additionally, the use of a gestational carrier allows the patient to avoid the maternal and fetal risks associated with pregnancy complicated by SCD. A gestational carrier either agrees to carry a pregnancy for another couple using the couple's embryos or to undergo insemination using sperm from the father or a donor. The goals are to avoid the maternal and fetal risks of SCD in the mother as well as avoiding the possibility of SCD in the offspring. (See  <a class="medical medical_review" href="/z/d/html/7431.html" rel="external">"Gestational carrier pregnancy"</a>.)</p><p class="headingAnchor" id="H1968472907"><span class="h2">Baseline health assessment and risks to the patient</span></p><p class="headingAnchor" id="H1312831110"><span class="h3">Maternal risks</span><span class="headingEndMark"> — </span>SCD affects multiple organ systems and is generally associated with an increased risk of SCD-related morbidity during pregnancy  (<a class="graphic graphic_table graphicRef140441" href="/z/d/graphic/140441.html" rel="external">table 1</a>). </p><p>Meta-analyses have found increased risk of maternal deaths and obstetric and fetal complications compared with controls who do not have SCD [<a href="#rid9">9,10</a>]. Individuals with underlying cardiomyopathy, pulmonary hypertension, or infection are particularly vulnerable to decompensation at delivery and in the first postpartum week. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaso-occlusive events</strong> – Vaso-occlusive or acute painful episodes increase during pregnancy and are the most common maternal SCD complications, occurring in over 50 percent of pregnancies [<a href="#rid11">11-18</a>]. Compared with the nonpregnant state, pregnancy in an individual with SCD is associated with increased risk of vaso-occlusive pain episodes, acute chest syndrome, and venous thromboembolism (VTE). The rate of vaso-occlusive pain episodes and acute chest syndrome is highest in the third trimester and up to one week after delivery; these account for 90 percent of pain and acute chest syndrome events during pregnancy and postpartum [<a href="#rid12">12,19</a>]. The risk of vaso-occlusive events may be increased in multiple gestation [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous and arterial thromboembolism</strong> – SCD confers a similar risk of venous thromboembolism (VTE) as a high-risk thrombophilia, as well as a possibly increased risk of arterial thromboembolism.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2023 study using administrative claims data for 6388 people with SCD and 17,110 age- and race-matched controls who were followed during pregnancy through the first year postpartum, the rates of VTE and arterial thromboembolism were increased substantially [<a href="#rid21">21</a>]: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>VTE – 11.3 percent, versus 1.2 percent in controls</p><p class="bulletIndent3"><span class="glyph">-</span>Arterial thromboembolism – 5.2 percent, versus 0.6 percent in controls</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a large retrospective study from 2008, the odds ratio (OR) for DVT in pregnant individuals with SCD was 2.5 (95% CI 1.5-4.1) [<a href="#rid22">22</a>]. Cerebral vein thrombosis was also increased (OR 4.9, 95% CI 2.2-10.9).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The risk of postpartum VTE in individuals with a major risk factor such as SCD who have a cesarean birth is estimated to be &gt;3 percent [<a href="#rid23">23</a>]. </p><p></p><p class="bulletIndent1">Venous thromboembolism prophylaxis is discussed below. (See <a class="local">'VTE prophylaxis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – In the 2008 study above, pregnant individuals with SCD had increased risks of the following infections compared with pregnant individuals without SCD [<a href="#rid22">22</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pneumonia (OR 9.8, 95% CI 8.0-12.0)</p><p class="bulletIndent2"><span class="glyph">•</span>Sepsis (OR 6.8, 95% CI 4.4-10.5)</p><p class="bulletIndent2"><span class="glyph">•</span>Asymptomatic bacteriuria (OR 6.8, 95% CI 3.1-14.9)</p><p class="bulletIndent2"><span class="glyph">•</span>Genitourinary tract infection (OR 2.3, 95% CI 1.9-2.7)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy complications</strong> – A meta-analysis found increased risks of preeclampsia (OR 2.05, 95% CI 1.47-2.85) and eclampsia (OR 3.02, 95% CI 1.20-7.58) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1">The cesarean birth rate tends to be higher in individuals with SCD. The increased rate may be related to a higher frequency of pregnancy complications, along with other factors. Some centers have policies for a short trial of labor and early operative intervention at the first sign of a nonreassuring fetal heart rate tracing in individuals with SCD [<a href="#rid24">24</a>]. (See <a class="local">'Vaginal versus cesarean birth'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – SCD is associated with increased risks of maternal death in observational studies, although SCD may be a surrogate for decreased access to health care, racial bias, or other health care disparities. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2015 meta-analysis of cohort studies that included over 26,800 pregnancies in individuals with SCD and 26 million pregnancies in individuals without SCD found a relative risk (RR) of death associated with SCD of 5.98 (95% CI 1.94-18.44) [<a href="#rid9">9</a>]. SCD may be a surrogate for decreased access to health care; higher maternal mortality risk was most pronounced in regions with lower gross national income in this and other studies [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2015 study from Ghana reported maternal death in two of 149 patients with SCD, which corresponds to a maternal mortality ratio of 1300 maternal deaths per 100,000 live births [<a href="#rid2">2</a>]. By comparison, in 2017, the overall maternal mortality ratio for Ghana was 308 per 100,000 live births and for the United States 19 per 100,000 live births [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2008 study from the United States that included nearly 18,000 deliveries with a discharge diagnosis of SCD and 17 million deliveries without SCD found a disproportionate rate of maternal deaths associated with SCD (1 percent of maternal deaths, despite accounting for only 0.1 percent of pregnancies) [<a href="#rid22">22</a>]. There were 10 deaths in the SCD group (72 deaths per 100,000 deliveries versus 12.7 deaths per 100,000 deliveries without SCD). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study of data from the United States National Inpatient Sample (2012 to 2018) that included 3901 deliveries in people with SCD among a total of over 5 million deliveries found that the maternal mortality ratio in the SCD group was 26 times greater than in the non-Black control group without SCD and &gt;10 times greater than in Black pregnant people without SCD (SCD: 133 deaths per 100,000 deliveries, Black race without SCD: 12 deaths per 100,000 deliveries, non-Black race without SCD: 5 deaths per 100,000 deliveries) [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1">The majority of deaths during pregnancy in SCD are sudden. Acute respiratory failure, often associated with acute chest syndrome or pulmonary embolism, is commonly described [<a href="#rid27">27-30</a>]. Acute multiorgan failure is often present. </p><p></p><p>SCD genotype may affect complication rates, as in nonpregnant individuals, but any individual with SCD may experience complications. Some studies have suggested a lower risk of complications with Hb SC disease than Hb SS, but others have not found differences [<a href="#rid11">11,19,31-33</a>]. </p><p>Sickle cell trait has not been found to be an independent risk factor for pregnancy complications other than urinary tract infections and possibly VTE.</p><p class="headingAnchor" id="H4150303138"><span class="h3">Pediatric outcomes</span><span class="headingEndMark"> — </span>A pooled analysis of 16 studies conducted through 2014 revealed the following increased pediatric risks in SCD pregnancies [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Perinatal mortality (OR 3.76, 95% CI 2.34-6.06).</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal growth restriction (OR 2.79, 95% CI 1.85-4.21).</p><p class="bulletIndent1"><span class="glyph">●</span>Preterm birth (OR 2.14, 95% CI 1.56-2.94).</p><p class="bulletIndent1"><span class="glyph">●</span>Low birthweight (OR 2.00, 95% CI 1.42-2.83).</p><p></p><p class="headingAnchor" id="H3256918069"><span class="h3">Pre-pregnancy evaluations</span><span class="headingEndMark"> — </span>The following evaluations are generally performed  (<a class="graphic graphic_table graphicRef140441" href="/z/d/graphic/140441.html" rel="external">table 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood pressure</strong> – Measurement of baseline blood pressure. Hypertension may be due to sickle nephropathy and is a risk factor for stroke and development of superimposed preeclampsia. (See  <a class="medical medical_review" href="/z/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney"</a> and  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Stroke and TIA'</a> and  <a class="medical medical_review" href="/z/d/html/116432.html" rel="external">"Chronic hypertension in pregnancy: Prenatal and postpartum care", section on 'Patients with superimposed preeclampsia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete blood count (CBC) and ferritin</strong> – Individuals with SCD should have routine monitoring of hemoglobin or hematocrit. Ferritin levels may increase due to increased iron stores from transfusional iron overload. Iron deficiency is also possible but less common; reports from low- and middle-income settings where chronic blood transfusion is not used have documented that a significant proportion of individuals with SCD start pregnancy with iron deficiency anemia. Individuals with excess iron stores may benefit from treatment prior to becoming pregnant (or in delaying pregnancy until treatment is discontinued). (See  <a class="medical medical_review" href="/z/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Chelation therapy'</a> and <a class="local">'Other medicines to start or stop'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney function </strong>– Chemistry panel, urinalysis, and creatinine to determine baseline organ function, particularly sickle nephropathy [<a href="#rid34">34</a>]. We obtain a baseline assessment of urinary protein excretion (eg, spot urine for protein to creatinine ratio or albumin to creatinine ratio). Urine albumin is less sensitive but may be used if resources are limited. Knowledge of baseline parameters is important because both pregnancy and preeclampsia (which is common in SCD patients) may worsen kidney function. (See  <a class="medical medical_review" href="/z/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney"</a> and  <a class="medical medical_review" href="/z/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary function </strong>– SCD management guidelines do not recommend routine pulmonary function tests prior to pregnancy; however, low forced expiratory volume in one second (FEV<sub>1</sub>) in adults with SCD is known to be associated with earlier death and is predictive of acute chest syndrome [<a href="#rid35">35</a>]. Thus, at a minimum, baseline FEV<sub>1</sub> measurement and pulse oximetry are desirable because pregnancy in individuals with SCD carries increased risks of pulmonary embolism, acute chest syndrome, and broncho-reactive lung disease [<a href="#rid36">36</a>]. The underlying obstructive and restrictive airway disease in SCD as well as the physiological changes in lung function may have significant impact on pregnancy outcome; as an example, FEV<sub>1</sub> &lt;60 of predicted value during pregnancy is associated with stillbirth [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Pulmonary complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urine culture</strong> – Asymptomatic bacteriuria and urinary tract infections are more common in individuals with SCD. (See  <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">"Urinary tract infections and asymptomatic bacteriuria in pregnancy", section on 'Asymptomatic bacteriuria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral and sexually transmitted diseases</strong> – All pregnant individuals, regardless of hemoglobinopathy status, are routinely screened for viral and sexually transmitted diseases including HIV, hepatitis B and C, and syphilis. (See  <a class="medical medical_review" href="/z/d/html/448.html" rel="external">"The preconception office visit", section on 'Laboratory assessment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood bank testing</strong> – Individuals with SCD have often received multiple transfusions and may have developed alloantibodies. These may complicate pretransfusion testing and identification of compatible red blood cell (RBC) units, as well as increase the risk of hemolytic disease of the fetus and newborn (HDFN), depending on whether the fetus expresses RBC antigens (due to variants inherited from the father) to which the mother carries alloantibodies [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'RBC antigen matching'</a> and  <a class="medical medical_review" href="/z/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Alloimmunization and hemolysis'</a>.)</p><p></p><p class="bulletIndent1">Pretransfusion testing and extended phenotypic matching (for RhD, C, E, and Kell antigens) is appropriate to facilitate transfusion if needed. Additional analyses such as molecular testing for RhD variants that create incomplete antigens may also be appropriate [<a href="#rid38">38-42</a>]. Discussion with a transfusion medicine and/or maternal-fetal medicine specialist may be warranted. (See <a class="local">'Maternal care'</a> below.)</p><p></p><p class="bulletIndent1">If RBC alloantibodies are present, the father should be tested for the corresponding antigens and a determination made of whether there is a risk for HDFN [<a href="#rid43">43</a>]. Management is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">"Management of non-RhD red blood cell alloantibodies during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retinal evaluation</strong> – Early proliferative sickle retinopathy may worsen during pregnancy, and a dilated retinal examination by an ophthalmologist is appropriate if not done in the previous year. (See  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Retinopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiogram</strong> – We generally perform a screening echocardiogram in individuals with possible symptoms of pulmonary hypertension (dyspnea or chest pain at rest or with exertion, sleep-disordered breathing, syncope or presyncope) and asymptomatic individuals with a history of pulmonary embolism, recurrent acute chest syndrome, or resting hypoxemia, consistent with a 2022 practice advisory from the American College of Obstetricians and Gynecologists (ACOG) [<a href="#rid44">44</a>]. </p><p></p><p class="bulletIndent1">There are no formal guidelines to screen for pulmonary hypertension in individuals with SCD prior to pregnancy. Limited preliminary evidence justifies screening with an echocardiogram for pulmonary hypertension and early cardiac dysfunction, which are associated with increased mortality during pregnancy [<a href="#rid45">45</a>]. Until additional evidence becomes available, we favor an individualized approach to determining the use of echocardiography. (See  <a class="medical medical_review" href="/z/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Cardiac complications'</a>.)</p><p></p><p class="headingAnchor" id="H3690164631"><span class="h2">Vaccines and medication management</span></p><p class="headingAnchor" id="H4021564139"><span class="h3">Vaccines</span><span class="headingEndMark"> — </span>Immunization status should be reviewed and updated, as needed, to comply with current guidelines. Polyvalent pneumococcal, Haemophilus influenza type B, and meningococcal vaccines are recommended for pregnant patients with SCD. Additional vaccines appropriate for all pregnant individuals, including COVID-19, influenza, tetanus, diphtheria, and pertussis, should follow the latest guidelines from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Pregnancy should be avoided for at least four weeks after administration of any live vaccine, such as the live-attenuated influenza vaccine, and no live vaccines should be administered during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a> and  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy"</a>.)</p><p class="headingAnchor" id="H604614720"><span class="h3">Hydroxyurea</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> (hydroxycarbamide) is the major disease modifying therapy for SCD; it has been clearly demonstrated to improve survival and to reduce the incidence of acute chest syndrome, vaso-occlusive pain, and other complications. (See  <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Evidence for efficacy'</a>.)</p><p>Discussions regarding continuing or temporarily stopping <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> are appropriate for both parents and should occur before conception. Education should be provided based on the latest available evidence and guidance, with shared decision-making. The following may be relevant:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Females</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fetal risks</strong> – Evidence regarding the effect of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> on the risk of congenital anomalies is limited to animal studies and small numbers of case reports; reports of prenatal exposure to hydroxyurea, alone or in combination with other drugs, are few. </p><p></p><p class="bulletIndent2">A 2022 review of 1788 pregnancies in individuals with SCD documented that 241 (16 percent) occurred while the mother was taking <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid46">46</a>]. On multivariate analysis, use of hydroxyurea at conception (including the month prior to conception) and continuing during pregnancy was associated with an increased risk of miscarriage or stillbirth (odds ratio [OR] 2.21, 95% CI 1.40-3.47) and an increased risk of low birth weight (&lt;5.5 pounds/2500 grams) in full-term live born infants (OR 2.98, 95% CI 1.09-7.38), but not with increased risk for preterm birth, serious medical problems, or congenital anomalies. The increased risks for miscarriage, stillbirth, and low birth weight were not observed in patients who only used hydroxyurea up to the time of conception and stopped it once aware of the pregnancy. These associations do not demonstrate causality, as individuals who continued to take hydroxyurea during pregnancy may have had other risk factors or comorbidities that affected outcomes.</p><p></p><p class="bulletIndent2">An increase in congenital anomalies was not seen in the 2022 study and a 2021 study of similar size [<a href="#rid46">46,47</a>]. However, animal studies have demonstrated teratogenic effects of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> when administered during organogenesis [<a href="#rid48">48-51</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Whether to discontinue</strong> – The choice to continue or discontinue <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> must balance the risks of vaso-occlusive complications, which could in turn harm the fetus, and direct fetal harm from the medication itself. Other considerations include how quickly the individual will become pregnant, which impacts the length of time they would be deprived of a disease-modifying therapy, and the presence (and spectrum) of RBC alloantibodies, which could impact the ability to find compatible RBC units for transfusion as an alternative to hydroxyurea.</p><p></p><p class="bulletIndent2">We generally do not discontinue <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> during pregnancy, since we are unaware of direct evidence of teratogenicity in humans, whereas evidence is very strong for increased vaso-occlusive complications without hydroxyurea. However, each individual must consider the risks and benefits for their individual situation. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Continuing the medication may be acceptable for individuals with frequent or severe vaso-occlusive complications.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Discontinuing may be acceptable for those with mild disease (eg, sickle-beta<sup>+</sup> thalassemia) who place a high value on avoiding unknown effects on fetal development or pregnancy loss. </p><p></p><p class="bulletIndent2">The 2014 SCD guideline suggests that <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> should not be used during pregnancy and breastfeeding but notes that the quality of the evidence was low [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing</strong> – Individuals who choose to discontinue <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> may stop the medication as early as three months prior to attempted conception. Since the greatest time of potential risk of miscarriage or teratogenesis is the first trimester, discontinuation at the time of conception is another option. Resumption may occur after delivery (longer interval without hydroxyurea), or during the second and third trimesters (shorter interval without hydroxyurea). The risk-benefit calculation may change in the second and third trimesters, where teratogenicity is no longer a major concern and vaso-occlusive pain events and acute chest syndrome are more frequent.</p><p></p><p class="bulletIndent2">Use of <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> during breastfeeding is also of unclear risk. Shared decision-making should occur to determine the overall best plan for the mother and infant, including potential benefits of breastfeeding for both the mother and infant. Evidence is discussed below. (See <a class="local">'Breastfeeding'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Males</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risks</strong> – Some observational studies have suggested that <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> can reduce sperm counts and sperm motility, with improvement after hydroxyurea is discontinued (a reversible effect) [<a href="#rid52">52-56</a>]. A 2022 Cochrane review concluded there was insufficient evidence to conclude whether hydroxyurea affects fertility [<a href="#rid57">57</a>]. SCD may independently affect sperm quality [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Whether to discontinue</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Fetal outcomes</strong> – We believe there is a very low risk of adverse fetal outcomes if the father has SCD and is taking <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> during attempted conception [<a href="#rid58">58</a>]. In contrast, continuing hydroxyurea may reduce vaso-occlusive complications in the father. Fathers can make an informed decision about whether to discontinue hydroxyurea during attempted conception based on available research and their own clinical status.  </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Paternal outcomes</strong> – Data and decision-making related to possible effects on fertility are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Fertility'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing</strong> – If a decision is made to discontinue <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, a suggested interval is three to six months prior to attempted conception.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regular transfusions as an alternative to </strong><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> – For individuals who choose to discontinue hydroxyurea and experience (or expect to experience) an increase in vaso-occlusive complications, regular blood transfusions may be an alternative, provided that phenotypically matched blood is available and transfusions are feasible. Other individuals may choose to reserve transfusions for acute complications. </p><p></p><p class="headingAnchor" id="H4126326681"><span class="h3">Other medicines to start or stop</span><span class="headingEndMark"> — </span>All medications should be reviewed and discussed to ensure that there is an opportunity to stop potentially harmful medications (after appropriate risk-benefit discussion) and appropriate medicines such as <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> are being taken at the optimal dose.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydroxyurea</strong> – Discussed above. (See <a class="local">'Hydroxyurea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Start or continue</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prenatal vitamins; iron only if needed</strong> – Individuals with SCD can take a prenatal vitamin, but they may need to supplement with extra <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>, as discussed below. If the ferritin level is increased (or iron overload is known to be present), they should use a prenatal vitamin without iron. </p><p></p><p class="bulletIndent2">Individuals with iron deficiency should be treated with iron. In limited resource settings, where the cost of iron studies may be prohibitive, selected use of iron supplementation is offered to patients when the clinical assessment suggests iron deficiency. (See  <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">"Anemia in pregnancy", section on 'Treatment of iron deficiency'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Folic acid</strong> – All individuals who are or may become pregnant are advised to take supplemental <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> to reduce the risks of neural tube defects. Individuals with SCD also have chronic hemolytic anemia, which further increases folate requirements. There is consensus among experts that individuals with SCD should take a higher dose of folic acid (4 mg daily, rather than 0.4 to 0.8 mg daily that is recommended for individuals without SCD or in prenatal vitamins [1 mg]) [<a href="#rid59">59,60</a>]. We provide this dose for the entire pregnancy, due to ongoing increased RBC turnover. In low-resource settings, especially in sub-Saharan Africa where the combined effects of SCD, malaria, and malnutrition may compound the risk of anemia, 4 mg folic acid daily, started at least three months before pregnancy, may be vital [<a href="#rid61">61</a>]. A 2020 guideline from the European Hematology Association recommends using at least 0.8 to 1 mg of folic acid daily in high-resource settings [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Analgesics</strong> – SCD can cause chronic and severe vaso-occlusive pain that must be adequately controlled. In general, therapies used when the individual is not pregnant can be continued, with the exception of nonsteroidal antiinflammatory drugs (NSAIDs), which can have adverse fetal effects when used for &gt;48 hours, particularly after 30 weeks. Details of the pain evaluation (to help determine whether pain is due to vaso-occlusion or another complication) and management (including use of a pain plan) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/110699.html" rel="external">"Evaluation of acute pain in sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">"Acute vaso-occlusive pain management in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent2">Management of pain episodes during pregnancy is discussed below. (See <a class="local">'Prevention and treatment of acute painful episodes'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Malaria prevention, if indicated</strong> – (See  <a class="medical medical_review" href="/z/d/html/4812.html" rel="external">"Malaria in pregnancy: Prevention and treatment"</a> and  <a class="medical medical_review" href="/z/d/html/99489.html" rel="external">"Sickle cell disease in sub-Saharan Africa", section on 'Malaria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinue</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ACE inhibitors and ARBs</strong> – Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are known human teratogens that should not be used during pregnancy. Individuals using these agents should be switched to an alternative medication, ideally at least one month before attempted conception. Extended-release <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a>, and <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a> are antihypertensive medications with a good safety profile in pregnancy. (See  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney", section on 'Hypertension'</a> and  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Choice and safety by drug class'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Iron chelators</strong> – Use of iron chelation is rare in individuals attempting conception. If an individual is taking an iron chelating agent, they can discontinue it when they become pregnant. In animal studies, <a class="drug drug_general" data-topicid="8794" href="/z/d/drug information/8794.html" rel="external">deferasirox</a> did not increase the risk of congenital anomalies at doses lower than those used in humans, but <a class="drug drug_general" data-topicid="9327" href="/z/d/drug information/9327.html" rel="external">deferoxamine</a> was associated with congenital anomalies [<a href="#rid63">63,64</a>]. Exposure data are limited in humans, but no toxic or teratogenic effects have been reported [<a href="#rid65">65</a>]. Individuals with excessive iron stores should consider delaying pregnancy until iron stores have been reduced. (See  <a class="medical medical_review" href="/z/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Excessive iron stores'</a>.)</p><p></p><p class="bulletIndent1">Individuals of reproductive potential who are taking these medications should keep close track of their menstrual cycles and take a pregnancy test if menses are late.</p><p></p><p>Most individuals with SCD discontinue prophylactic penicillin at approximately age five years, and we do not initiate penicillin during pregnancy.</p><p class="headingAnchor" id="H3059816993"><span class="h2">Sickle cell trait</span><span class="headingEndMark"> — </span>It is not clear whether individuals with sickle cell <strong>trait </strong>require any modification to routine pre-pregnancy or pregnancy care because of their carrier status, with the exception of genetic counseling, paternal hemoglobinopathy testing, and maternal urine culture once per trimester. (See <a class="local">'Counseling prior to pregnancy'</a> above and <a class="local">'Likelihood of SCD in offspring and reproductive options'</a> above and <a class="local">'Maternal care'</a> below.)</p><p>A study that reviewed medical records of Black females with sickle cell trait and Black females without sickle cell trait did not find an association of sickle cell trait with increased risk of VTE; however, the study was underpowered to detect small differences [<a href="#rid66">66</a>]. In a nonpregnant population, others have observed an increased risk of VTE (albeit weak) in African Americans with sickle cell trait compared with controls [<a href="#rid67">67,68</a>]. This should be taken into consideration but generally does not warrant pharmacologic VTE prophylaxis based on sickle cell trait alone. (See  <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Venous thromboembolism'</a> and <a class="local">'VTE prophylaxis'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h1">DURING PREGNANCY</span></p><p class="headingAnchor" id="H1058765"><span class="h2">Maternal care</span><span class="headingEndMark"> — </span>Complication risks vary from individual to individual and may be lower with certain genotypes (Hb SC or Hb S-beta<sup>+</sup> thalassemia); all pregnancies in individuals with SCD are considered high risk and warrant the higher level of expertise of a maternal-fetal medicine physician and access to multidisciplinary care. </p><p>Implementation of active management protocols for pregnancy in SCD have demonstrated survival benefits, such as a decrease in the mortality rate from 27 percent to 1.8 percent in Benin, Africa [<a href="#rid69">69</a>]. A multidisciplinary care protocol in Ghana resulted in a nearly 90 percent reduction in the risk of maternal death [<a href="#rid3">3</a>]. A 2022 meta-analysis of studies from low- and middle-income countries showed that multidisciplinary care resulted in consistently lower maternal and perinatal mortality rates for individuals with SCD compared with lack of multidisciplinary care [<a href="#rid70">70</a>]. </p><p>In the SCD obstetric care protocol by the obstetric SCD comprehensive program in Ghana, we provide a joint antenatal review by an obstetrician with experience in high-risk pregnancy and a hematologist with interest in SCD in a program coordinated by the SCD nurse [<a href="#rid71">71</a>]. We advocate a similar approach elsewhere. </p><p>Care includes the following  (<a class="graphic graphic_table graphicRef140441" href="/z/d/graphic/140441.html" rel="external">table 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline health assessment and counseling</strong> – Baseline health assessments and counseling are provided if not done prior to conception. Even if counseling was provided, there may be a benefit of reviewing information and allowing the individual to ask additional questions. (See <a class="local">'Baseline health assessment and risks to the patient'</a> above and <a class="local">'Counseling prior to pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine prenatal evaluations</strong> – Individuals with SCD should be provided with the same routine prenatal care as the general obstetric population; these are listed separately. (See  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment"</a> and  <a class="medical medical_review" href="/z/d/html/83303.html" rel="external">"Prenatal care: Second and third trimesters"</a> and  <a class="medical medical_review" href="/z/d/html/112420.html" rel="external">"Prenatal care: Patient education, health promotion, and safety of commonly used drugs"</a>.)</p><p></p><p class="bulletIndent1">Pregnancies with maternal alloantibodies (or a history of alloantibodies) should be evaluated for risk of hemolytic disease of the fetus and newborn (HDFN) and managed accordingly. In addition, the blood bank should be notified so that compatible blood is available for transfusion, if needed. (See  <a class="medical medical_review" href="/z/d/html/6820.html" rel="external">"RhD alloimmunization in pregnancy: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">"Management of non-RhD red blood cell alloantibodies during pregnancy"</a> and <a class="local">'Transfusion therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCD-specific evaluations</strong> – Early detection of SCD complications is essential, as is distinguishing pregnancy complications from SCD complications. As an example, in patients with neurological signs and symptoms, it is important to distinguish preeclampsia with severe features from cerebrovascular disease related to SCD. (See  <a class="medical medical_review" href="/z/d/html/5926.html" rel="external">"Acute stroke (ischemic and hemorrhagic) in children and adults with sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis", section on 'Neurologic'</a>.)</p><p></p><p class="bulletIndent1">Given the possibility of placental ischemia, monitoring fetal growth with ultrasound and fetal well-being with nonstress tests or biophysical profile scoring is recommended during the third trimester [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/z/d/html/6768.html" rel="external">"Fetal growth restriction: Evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a>.) </p><p></p><p class="bulletIndent1">Management of preeclampsia, placental abruption, or fetal growth restriction is the same as for individuals without SCD. (See  <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a> and  <a class="medical medical_review" href="/z/d/html/6803.html" rel="external">"Acute placental abruption: Management and long-term prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome", section on 'Prenatal care'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain plan</strong> – It is useful to have an individualized pain care plan available to all clinicians who may be responsible for the patient if they have a vaso-occlusive painful episode. Individualized pain care plans should provide a sequence of medications to try at home and an algorithm for when to send the patient to a day hospital (or emergency department), with opioid doses and other interventions. (See  <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">"Acute vaso-occlusive pain management in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydration </strong>– Adequate hydration should be advised. During pregnancy, adequate fluid intake is estimated to be approximately 2.3 L/day (76 fluid ounces or approximately 10 cups). Additional water is consumed in foods to meet the total adequate intake of 3 L/day. Ambient temperature, humidity, exercise, and other physical activity should also be taken into consideration in determining the daily total fluid requirement. If there is nausea or vomiting, we err on the side of aggressive treatment. (See  <a class="medical medical_review" href="/z/d/html/453.html" rel="external">"Nutrition in pregnancy: Dietary requirements and supplements", section on 'Fluid requirements'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin testing and transfusion plan</strong> – Hemoglobin is monitored monthly. For those receiving chronic transfusions, the percentage of Hb S should also be determined.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Iron</strong> – Individuals receiving chronic or intermittent transfusions are unlikely to have iron deficiency. In regions of the world where transfusion for SCD is not commonly used, evaluation of iron status may be appropriate and may inform decision-making about the need for iron supplementation [<a href="#rid74">74</a>]. If the ferritin is low, indicating iron deficiency, then treatment is appropriate. Pregnancy and SCD both increase ferritin levels, and revised normal ranges may be required. If iron overload is present, prenatal vitamins without iron should be used. (See  <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">"Anemia in pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transfusions</strong> – Indications for transfusion should be clearly documented in the patient's medical record. The main purpose of transfusion is to reduce the percentage of Hb S and decrease vaso-occlusive complications, as well as to treat severe anemia and acute blood loss. Data on obstetric outcomes (stillbirth, growth restriction, preterm birth) are limited to a single trial that did not show an effect [<a href="#rid75">75</a>]. Details are discussed below. (See <a class="local">'Transfusion therapy'</a> below.)</p><p></p><p class="bulletIndent2">Close communication with the transfusion service helps ensure that compatible blood is available for transfusion if needed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Individuals with SCD and sickle cell <strong>trait</strong> are at risk for bacteriuria and hematuria. Screening and treatment of bacteriuria are indicated because asymptomatic bacteriuria during pregnancy increases the risk of pyelonephritis and has been associated with preterm birth and low birth weight infants. (See  <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">"Urinary tract infections and asymptomatic bacteriuria in pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If bacteriuria is present on initial urine culture, we provide antibiotic therapy and retest monthly until delivery. If bacteriuria recurs or persists, we give suppressive therapy for the remainder of pregnancy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the initial urine culture is negative, some clinicians screen once per month and some screen once per trimester each trimester [<a href="#rid73">73</a>]. We do a culture once every four to six weeks in individuals with SCD and once per trimester in those with sickle cell trait. (See  <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">"Urinary tract infections and asymptomatic bacteriuria in pregnancy", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hydroxyurea</strong> – (See <a class="local">'Hydroxyurea'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Folic acid</strong> – <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a> is continued during pregnancy (typical dose for individuals with SCD who are pregnant, 4 mg daily). (See <a class="local">'Other medicines to start or stop'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low-dose </strong><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> – The incidence of preeclampsia is high in individuals with SCD (approximately 10 to 33 percent based on meta-analyses) [<a href="#rid10">10,76</a>]. We administer low-dose aspirin daily from the beginning of the second trimester or after 12 weeks, unless contraindicated [<a href="#rid77">77</a>]. This is consistent with multiple medical society guidelines. Dosing and supporting evidence are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Low-dose aspirin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LMW heparin</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>During hospitalization</strong> – Unless contraindicated, all hospitalizations except labor and delivery should include venous thromboembolism (VTE) prophylaxis. (See  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Thromboembolism prophylaxis'</a>.)</p><p></p><p class="bulletIndent3">VTE prophylaxis around the time of delivery and postpartum is discussed below. (See <a class="local">'VTE prophylaxis'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Ambulatory/outpatients</strong> – Patients with SCD have an increased risk of VTE, and VTE prophylaxis during the entire pregnancy is appropriate for some high-risk patients (such as those with a history of VTE or a high-risk thrombophilia). (See  <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Patients who are pregnant'</a> and  <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Prevention of VTE'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">Anti-D immune globulin</a> – Recommendations are the same as for individuals without SCD. (See  <a class="medical medical_review" href="/z/d/html/6820.html" rel="external">"RhD alloimmunization in pregnancy: Overview"</a> and  <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">"RhD alloimmunization: Prevention in pregnant and postpartum patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Home-based prophylactic oxygen therapy</strong> – In SCD, oxygen demands may be increased due to several factors including anemia, sleep-disordered breathing, nocturnal desaturations, hypoxia, and/or asthma. Preliminary data from a retrospective study suggest that prophylactic nocturnal oxygen therapy may decrease transfusion requirements and complications, particularly in high-risk individuals, but this is not routinely practiced [<a href="#rid78">78</a>]. In this study, oxygen was administered at 2 to 3 L/minute via an appropriately sized nose piece. </p><p></p><p class="headingAnchor" id="H113604888"><span class="h2">Prenatal (fetal) diagnosis of SCD</span><span class="headingEndMark"> — </span>Invasive and noninvasive methods for diagnosis of SCD in the fetus are available if this information would inform decisions about termination of pregnancy or if the mother desires this information for other reasons. SCD does not present until approximately six months of age (when beta globin production increases), so there are no known implications for fetal health. (See  <a class="medical medical_review" href="/z/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chorionic villus sampling (CVS</strong>) – Performed at 10 to 14 weeks of gestation. (See  <a class="medical medical_review" href="/z/d/html/449.html" rel="external">"Chorionic villus sampling"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amniocentesis</strong> – Can be performed as early as 15 to 16 weeks. (See  <a class="medical medical_review" href="/z/d/html/5390.html" rel="external">"Diagnostic amniocentesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell-free fetal DNA in maternal blood</strong> – Technology is available for single gene noninvasive prenatal testing (NIPT) for <em>HBB</em> (the beta globin gene) [<a href="#rid79">79-81</a>]. (See  <a class="medical medical_review" href="/z/d/html/445.html" rel="external">"Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis", section on 'Fetal diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H1617178053"><span class="h2">Spontaneous pregnancy loss (miscarriage) and termination</span><span class="headingEndMark"> — </span>Spontaneous pregnancy loss and termination are usually well-tolerated in individuals with SCD, but the risk of complications may be greater (eg, due to baseline anemia [<a href="#rid82">82</a>]).</p><p>We generally recommend surgical rather than medical management of spontaneous pregnancy loss or pregnancy termination, similar to all patients with bleeding disorders or severe anemia. In a randomized trial on medical versus surgical management of spontaneous pregnancy loss in the general population, surgical management was associated with overall less blood loss [<a href="#rid83">83</a>]. For this reason, we prefer surgical over medical management for individuals with severe anemias or bleeding disorders. </p><p>Details are presented separately. (See  <a class="medical medical_review" href="/z/d/html/128965.html" rel="external">"Pregnancy loss (miscarriage): Description of management techniques", section on 'Surgical management (uterine aspiration)'</a> and  <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">"First-trimester pregnancy termination: Uterine aspiration"</a>.) </p><p class="headingAnchor" id="H1058980"><span class="h2">Prevention and treatment of acute painful episodes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – The cornerstone of prevention includes use of disease-modifying therapies (see <a class="local">'Hydroxyurea'</a> above and <a class="local">'Transfusion therapy'</a> below) and avoiding precipitating factors. Dehydration, hypoxia, acidosis, infection, and cold should be avoided as they may precipitate an acute pain event [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – There are limited data on SCD pain management specific to pregnancy, and our approach to management parallels management in nonpregnant individuals [<a href="#rid84">84</a>]. Standard aspects of management include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prompt evaluation for precipitating factors (dehydration, hypoxia), potential causes (particularly infection), and alternative diagnoses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral or intravenous fluid resuscitation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aggressive and rapid pain control, similar to that used for individuals with SCD who are not pregnant [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Mild pain may be treated with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. Nonmedicinal strategies (massage, warm heating pads, mind-body techniques) may be sufficient to manage the pain or hasten recovery. Nonsteroidal antiinflammatory drug (NSAID) use should be minimized, but a short course (&lt;48 hours) is reasonable given the lack of a clearly safer alternative. Whether NSAID use in the first trimester increases the risk of miscarriage, cardiac anomalies, or gastroschisis is unclear; epidemiologic studies have reported conflicting results [<a href="#rid63">63</a>]. NSAIDs are generally avoided after approximately 30 weeks of gestation because of an increased risk of premature narrowing or closure of the ductus arteriosus and oligohydramnios. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a> and  <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">"Inhibition of acute preterm labor", section on 'Fetal side effects'</a>.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Moderate pain may be treated with <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">hydrocodone</a> with or without <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>. Nonmedicinal strategies may be a helpful adjunct.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For severe pain, opioids are the therapy of choice. Continuous infusion by patient-controlled analgesia (PCA) is useful because it provides the most even pain control within the therapeutic window without side effects, along with the option for self-administration of additional doses for breakthrough pain. However, PCA administration requires rigorous monitoring and appropriate expertise to determine the correct settings and avoid complications. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Epidural analgesia may be appropriate in some cases for extreme pain, but this is unusual. </p><p></p><p class="bulletIndent1">Routine use of oxygen is not indicated during an acute vaso-occlusive pain episode unless there is evidence of a clinically significant decrease in hemoglobin oxygen saturation from the individual's baseline (typically, of more than four percentage points). The rationale is that supplemental oxygen may mask a decline in clinical status or reduction in oxygen saturation and result in delays in care. Additional information about evaluating pain and treating vaso-occlusive pain is presented separately. (See  <a class="medical medical_review" href="/z/d/html/110699.html" rel="external">"Evaluation of acute pain in sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/7144.html" rel="external">"Acute vaso-occlusive pain management in sickle cell disease"</a>.)</p><p></p><p class="headingAnchor" id="H18580098"><span class="h2">Management of other complications of SCD</span><span class="headingEndMark"> — </span>Complications of SCD such as acute chest syndrome or infection are generally managed as in nonpregnant individuals. Maintaining a high index of suspicion and acting promptly is critical. Fever is a medical emergency as individuals with SCD are immunosuppressed due to functional asplenism. (See  <a class="medical medical_review" href="/z/d/html/5937.html" rel="external">"Evaluation and management of fever in children and adults with sickle cell disease", section on 'Risk of life-threatening infection'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and differential diagnosis</strong> – Early evidence of impaired pulmonary, liver, kidney, or central nervous system function should be considered a sign of an impending life-threatening event, and investigation for the cause of the worsening function should be undertaken immediately [<a href="#rid30">30</a>]. Concern about the possible effects of ionizing radiation should not prevent medically indicated diagnostic imaging studies using the best available modality for the clinical situation. Although ultrasound and magnetic resonance imaging are preferred in pregnancy, when imaging studies requiring ionizing radiation are necessary, various techniques can be employed to minimize the radiation dose. </p><p></p><p class="bulletIndent1">The standard differential diagnosis of SCD complications should be expanded to include pregnancy-related disorders. (See  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory symptoms may be due to acute chest syndrome, pulmonary embolism, cardiomyopathy, pulmonary hypertension, severe anemia, asthma exacerbation, or other causes. (See  <a class="medical medical_review" href="/z/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)"</a> and  <a class="medical medical_review" href="/z/d/html/89374.html" rel="external">"Pulmonary embolism in pregnancy: Clinical presentation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7121.html" rel="external">"Overview of the pulmonary complications of sickle cell disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neurologic changes (headache, visual changes, seizures) may be a component of multiorgan failure or may be due to transient ischemia, stroke, meningitis, or preeclampsia/eclampsia. (See  <a class="medical medical_review" href="/z/d/html/5926.html" rel="external">"Acute stroke (ischemic and hemorrhagic) in children and adults with sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5937.html" rel="external">"Evaluation and management of fever in children and adults with sickle cell disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver function abnormalities may be related to hepatic sequestration crisis, preeclampsia with severe features, or HELLP syndrome. (See  <a class="medical medical_review" href="/z/d/html/3589.html" rel="external">"Hepatic manifestations of sickle cell disease"</a> and  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a>.)</p><p></p><p class="bulletIndent1">A missed or delayed diagnosis of pulmonary embolism can pose a greater risk than the hazard associated with ionizing radiation. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a> and  <a class="medical medical_review" href="/z/d/html/89374.html" rel="external">"Pulmonary embolism in pregnancy: Clinical presentation and diagnosis", section on 'Diagnostic imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interventions</strong> – Pain should be treated effectively, and appropriate supportive care should be provided as needed (oxygen, hydration). (See <a class="local">'Prevention and treatment of acute painful episodes'</a> above.)</p><p></p><p class="bulletIndent1">Transfusion is appropriate for acute chest syndrome, acute stroke, multiorgan failure, and aplastic crisis. (See  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'</a>.)</p><p></p><p class="bulletIndent1">Individuals with SCD who require hospitalization for a complication (SCD-related or obstetric) should generally receive VTE prophylaxis with a low molecular weight (LMW) heparin or <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>, unless contraindicated. However, anticoagulation may preclude or delay administration of neuraxial anesthesia for labor and delivery. (See  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Thromboembolism prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a> and  <a class="medical medical_review" href="/z/d/html/14930.html" rel="external">"Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication"</a>.)</p><p></p><p class="bulletIndent1">Other interventions depend on the specific complication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication risks </strong>– The risks of specific medications used to treat or prevent these complications during pregnancy can be checked by searching the drug name in UpToDate and reading the reproductive and pregnancy considerations sections of the drug information topic. The pregnancy risks need to be weighed against the risks of alternative medications or no treatment. (See  <a class="medical medical_review" href="/z/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)"</a> and  <a class="medical medical_review" href="/z/d/html/5937.html" rel="external">"Evaluation and management of fever in children and adults with sickle cell disease"</a>.)</p><p></p><p class="headingAnchor" id="H1059444"><span class="h2">Transfusion therapy</span><span class="headingEndMark"> — </span>Transfusions are commonly used during pregnancy to treat acute complications, in preparation for surgery, and in selected preventive transfusion programs. </p><p>In most cases, the purpose of transfusion is to reduce the percentage of Hb S, not to increase the total Hb level. An exception is acute parvovirus infection, which can cause transient aplasia and severe anemia in individuals with chronic hemolytic anemia. </p><p>In fact, raising the Hb too high (&gt;10 mg/dL) may be detrimental to most individuals; the baseline Hb in many individuals with SCD is approximately 8 g/dL. Increased Hb can cause hyperviscosity syndrome. (See  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Risk of hyperviscosity syndrome from simple transfusion'</a>.)</p><p>Specific uses of transfusion include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute complications</strong> – Certain acute vaso-occlusive complications of SCD are treated with transfusions, which can decrease morbidity and in some cases mortality. Accepted indications for therapeutic transfusion therapy in individuals with SCD include acute stroke, acute chest syndrome, acute multiorgan failure, acute symptomatic anemia, reticulocytopenia (most commonly associated with Parvovirus B19 infection, but can occur with any infection), or following hepatic or splenic sequestration. (See  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Indications for transfusion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preparation for surgery</strong> – Simple transfusion is used prior to many surgeries in SCD. The rationale is based on improved outcomes, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Prophylactic preoperative transfusion'</a>.)</p><p></p><p class="bulletIndent1">Simple transfusion can also be used prior to scheduled cesarean birth. (See <a class="local">'Labor and delivery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic/prophylactic transfusion </strong>–<strong> </strong>Chronic prophylactic transfusions are one of the few effective disease-modifying therapies for SCD other than <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, and they may be needed in individuals with frequent vaso-occlusive complications (acute chest syndrome, acute pain episodes) who have temporarily stopped hydroxyurea during pregnancy. (See <a class="local">'Hydroxyurea'</a> above.)</p><p></p><p class="bulletIndent1">The routine use of chronic transfusions during pregnancy remains controversial, despite several observational studies and randomized trials, and there is no clear consensus on when to use this approach. The 2020 American Society of Hematology (ASH) guideline on transfusion in SCD suggests that regular transfusion be considered if there is a history of severe SCD-related complications, either prior to the current pregnancy or with previous pregnancies; or if other high-risk features are present such as other comorbidities or nephropathy [<a href="#rid86">86</a>]. In these individuals, transfusions may be given during the third trimester (when vaso-occlusive complications are most common) or earlier. (See <a class="local">'Maternal risks'</a> above.)</p><p></p><p class="bulletIndent1">Evidence for pregnancy outcomes (fetal growth restriction, preterm birth) is limited. Available evidence on maternal outcomes includes: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the seminal randomized trial including 72 pregnant patients with SCD, routine prophylactic transfusions led to a reduction in acute painful episodes (5 of 36 patients [14 percent] receiving chronic transfusions versus 18 of 36 controls [50 percent], p&lt;0.01) [<a href="#rid87">87</a>]. Other outcomes were not affected, but the number of patients and events was small. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2015 meta-analysis that included 12 observational studies (1291 patients) found that prophylactic transfusions were associated with reduced maternal mortality (odds ratio [OR] 0.23, 95% CI 0.06-0.91), reduced painful episodes (OR 0.26, 95% CI 0.09-0.76), and reduced pulmonary complications (OR 0.25, 95% CI 0.09-0.72) [<a href="#rid88">88</a>]. However, these studies had a moderate to high risk of bias and low event rates. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In <strong>nonpregnant</strong> individuals with SCD, chronic transfusions are effective in reducing some complications such as stroke in individuals at increased stroke risk [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/106228.html" rel="external">"Prevention of stroke (initial or recurrent) in sickle cell disease", section on 'Evidence for chronic transfusion'</a>.)</p><p></p><p>Potential reductions in adverse events must be weighed against the harms and burdens of transfusion, including transfusion reactions, risk of alloimmunization, hospitalization rate, and cost.</p><p>Transfusion techniques, including using leukoreduced RBCs, extended phenotypic matching, and choice between simple and exchange transfusion, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Transfusion techniques'</a>.)</p><p class="headingAnchor" id="H2523582488"><span class="h1">LABOR AND DELIVERY</span></p><p class="headingAnchor" id="H18078415"><span class="h2">Vaginal versus cesarean birth</span><span class="headingEndMark"> — </span>There are no medical contraindications to a trial of labor and vaginal birth, and in general, cesarean birth is reserved for standard obstetric indications. (See  <a class="medical medical_review" href="/z/d/html/4475.html" rel="external">"Cesarean birth: Preoperative planning and patient preparation", section on 'Indications'</a>.)</p><p>Discussion of the birth plan should be initiated early to allow an ongoing discussion. The plan should be individualized based on maternal and fetal health, and the patient should be prepared for the possibility that their plan may change over the course of the pregnancy and that cesarean birth may be necessary. Optimally, cesarean birth can be scheduled, but labor complications may necessitate an urgent/emergency procedure. </p><p class="headingAnchor" id="H4144672232"><span class="h2">Timing</span><span class="headingEndMark"> — </span>The risk of stillbirth and preeclampsia increases with increasing gestational age, but no high-quality studies have determined the optimal gestational age for delivery in individuals with SCD. </p><p>We generally recommend delivery at 37 to 39 weeks, with the exact timing decided on an individual basis. </p><p class="bulletIndent1"><span class="glyph">●</span>Evidence to support delivery at 39 weeks comes from the 2018 ARRIVE trial, which compared induction of labor at 39 weeks and 0 days to 39 weeks and 4 days of gestation versus expectant management for &gt;6000 low-risk nulliparous patients (general United States population, not SCD-specific) [<a href="#rid89">89</a>]. Induction at 39 weeks resulted in a reduction in cesarean birth, a reduction in hypertensive disorders of pregnancy, and a trend toward a reduction in the composite of perinatal death or severe neonatal complications, compared with expectant management. (See  <a class="medical medical_review" href="/z/d/html/4476.html" rel="external">"Induction of labor with oxytocin", section on 'At 39 weeks'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delivery closer to 37 weeks may be appropriate for individuals with high-risk genotypes (Hb SS or Hb S-beta<sup>0</sup>-thalassemia) or those with known SCD complications or comorbidities such as frequent vaso-occlusive episodes or hypertension. The reasoning is based on the high risk of placentally-mediated complications (growth restriction, oligohydramnios) [<a href="#rid90">90</a>]. </p><p></p><p class="headingAnchor" id="H2735351301"><span class="h2">Monitoring and supportive care</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion prior to cesarean birth</strong> – If there is time, simple transfusion prior to cesarean birth is reasonable in patients at increased risk of complications because of chronic lung disease, central nervous system disease, or multiorgan dysfunction. We target a hemoglobin of ≥8 g/dL, if possible, at one to two hours before delivery. Evidence from nonpregnant individuals with SCD demonstrates improved perioperative outcomes with preoperative transfusion, as discussed separately. (See <a class="local">'Transfusion therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Prophylactic preoperative transfusion'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal monitoring</strong> – Continuous intrapartum fetal heart rate monitoring is appropriate due to the high risk of complications. (See <a class="local">'Maternal risks'</a> above and <a class="local">'Pediatric outcomes'</a> above and  <a class="medical medical_review" href="/z/d/html/4446.html" rel="external">"Anesthesia for labor and delivery in high-risk heart disease: General considerations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing vaso-occlusive complications </strong>– The patient should be kept warm, hydrated, and well oxygenated to reduce the risk of acute pain events and other vaso-occlusive complications. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hydration</strong> – Adequate fluid intake (oral or parenteral) is important so the mother is well hydrated. Fluid balance is important because some individuals with SCD are at risk for fluid retention from subclinical cardiomyopathy [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Analgesia/anesthesia</strong> – Neuraxial anesthesia is useful to reduce maternal cardiac demands due to pain and anxiety during labor. For patients undergoing cesarean birth, neuraxial anesthesia is generally preferable to general anesthesia, but the choice is influenced by a variety of factors, such as the urgency of the procedure, maternal hemodynamic status, and physician and patient preference. (See  <a class="medical medical_review" href="/z/d/html/101803.html" rel="external">"Neuraxial analgesia for labor and delivery (including instrumental delivery)"</a> and  <a class="medical medical_review" href="/z/d/html/4468.html" rel="external">"Pharmacologic management of pain during labor and delivery"</a> and  <a class="medical medical_review" href="/z/d/html/4480.html" rel="external">"Anesthesia for cesarean delivery"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oxygen </strong>– Supplemental oxygen should be given as needed to maintain O<sub>2 </sub>saturation ≥95 percent. For cesarean births, intranasal oxygen should be given intraoperatively for regional anesthesia and continued for 12 to 24 hours after surgery. Incentive spirometry, every two hours while the patient is awake, should be instituted for 48 hours after cesarean birth to reduce the risk of acute chest syndrome [<a href="#rid71">71</a>]. Continuous positive airway pressure (CPAP) should be considered if chest signs and/or symptoms develop or if O<sub>2 </sub>saturation drops to &lt;92 percent [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/16353.html" rel="external">"Acute chest syndrome (ACS) in sickle cell disease (adults and children)", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – Antibiotic prophylaxis should follow local standards (ie, patients with SCD do not require more aggressive antibiotic therapy). (See  <a class="medical medical_review" href="/z/d/html/4475.html" rel="external">"Cesarean birth: Preoperative planning and patient preparation", section on 'Antibiotic prophylaxis'</a>.)</p><p></p><p class="headingAnchor" id="H370961114"><span class="h2">Cord blood</span><span class="headingEndMark"> — </span>An umbilical cord blood specimen collected at the time of birth can be used for newborn screening for hemoglobinopathy and other disorders (as an alternative to heel stick). Details of testing methodologies and interpretation are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders", section on 'Newborn screening'</a>.)</p><p>Umbilical cord blood also may be harvested for use in hematopoietic stem transplantation (HSCT) for a relative with SCD; cord blood can be used for HSCT if the child is unaffected with SCD or if they have sickle cell trait. (See  <a class="medical medical_review" href="/z/d/html/3531.html" rel="external">"Collection and storage of umbilical cord blood for hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H18579183"><span class="h1">POSTPARTUM CARE</span></p><p class="headingAnchor" id="H1937861116"><span class="h2">Surveillance for maternal complications</span><span class="headingEndMark"> — </span>Close maternal surveillance for infection and thromboembolism is important, especially after cesarean birth  (<a class="graphic graphic_table graphicRef140441" href="/z/d/graphic/140441.html" rel="external">table 1</a>). </p><p>Anorexia, nausea, urinary tract infection, wound infection, endometritis, and venous thromboembolism (VTE) are more common after cesarean than vaginal birth. The risk of fat and bone marrow embolism may increase during the postpartum period [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H2516491029"><span class="h2">VTE prophylaxis</span><span class="headingEndMark"> — </span>VTE risk is increased in individuals with SCD, as outlined above. (See <a class="local">'Maternal risks'</a> above.)</p><p>Based on this increased risk, for individuals with SCD, we follow the recommendations for postpartum VTE prophylaxis in high-risk populations and use prophylactic anticoagulation (typically, low molecular weight [LMW] heparin) [<a href="#rid93">93</a>]. VTE prophylaxis should be continued for six weeks postpartum. (See  <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Our approach to patients with high-risk thrombophilias'</a>.) </p><p>This is consistent with guidelines from the American Society of Hematology (ASH) and the American College of Obstetricians and Gynecologists (ACOG) on thromboembolism prevention in pregnancy, both of which recommend prophylactic anticoagulation postpartum in individuals with high-risk thrombophilias [<a href="#rid23">23,93,94</a>]. </p><p>Mechanical thromboprophylaxis (pneumatic compression) is recommended for all individuals undergoing cesarean birth and is suggested in addition to anticoagulation for those at highest risk of VTE due to multiple risk factors. Early ambulation and adequate hydration are also helpful.</p><p>Sickle cell trait is a weak risk factor for VTE but the risk is not great enough to warrant pharmacologic VTE prophylaxis based on sickle cell trait alone. Clinicians should take this into consideration but should follow the general protocols for VTE prevention in pregnancy. (See  <a class="medical medical_review" href="/z/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/7145.html" rel="external">"Sickle cell trait", section on 'Reproductive issues'</a>.) </p><p class="headingAnchor" id="H18579190"><span class="h2">Breastfeeding</span><span class="headingEndMark"> — </span>Breastfeeding should be encouraged for its maternal and infant health benefits. (See  <a class="medical medical_review" href="/z/d/html/5022.html" rel="external">"Maternal and economic benefits of breastfeeding"</a> and  <a class="medical medical_review" href="/z/d/html/5013.html" rel="external">"Infant benefits of breastfeeding"</a> and  <a class="medical medical_review" href="/z/d/html/4986.html" rel="external">"Initiation of breastfeeding"</a> and  <a class="medical medical_review" href="/z/d/html/4978.html" rel="external">"Breastfeeding: Parental education and support"</a>.)</p><p>While breastfeeding was previously discouraged in individuals taking <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, research from 2020 shows that there is very little transfer of hydroxyurea into breastmilk. In a study involving 16 individuals who were taking hydroxyurea, a mean of 2.2 mg of the drug was present in breastmilk for a 1000 mg daily maternal dose, corresponding to a relative infant dose of 3.4 percent, which is below the 5 to 10 percent safety threshold [<a href="#rid95">95</a>]. Approximately 1.2 mg are excreted during the first three hours after taking hydroxyurea; beyond hour 3, there is very little hydroxyurea in breast milk, and by hour 6 there is essentially none. Thus, as a precaution, the individual can take her daily dose immediately after a feeding or pumping or can consider a single after-dose pump and dump maneuver [<a href="#rid95">95</a>]. </p><p>The safety of other medications during breastfeeding can be checked by searching the drug name in UpToDate and reading the breastfeeding considerations section of the drug information topic, or by searching the drug name in other resources such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK501922%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trystKLNkAhaR%2FcduMJFFebszM73aaFBm717nqYa%2FpVDsg%3D%3D&amp;TOPIC_ID=7139" target="_blank">LactMed</a>. </p><p class="headingAnchor" id="H4072368372"><span class="h2">Restarting medications</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">Hydroxyurea</a> – If an individual was taking hydroxyurea prior to pregnancy and discontinued therapy during pregnancy, we restart hydroxyurea at the steady state dose the patient was on prenatally. This may be delayed during breastfeeding, or the individual may take the approach of breastfeeding while taking hydroxyurea, due to the health benefits of both and the very small amount of hydroxyurea in breast milk. This can be further reduced by timing the daily hydroxyurea dose just after feeding or pumping or considering a single after-dose pump and dump maneuver. (See <a class="local">'Breastfeeding'</a> above.)</p><p></p><p class="bulletIndent1">It may take as long as six months after restarting <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> to reach the full therapeutic effect. (See  <a class="medical medical_review" href="/z/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Increased Hb F production'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron chelation</strong> – Individuals who were taking an iron chelator prior to pregnancy should have their iron status reevaluated postpartum, since pregnancy depletes at least 1 to 2 grams of iron. (See  <a class="medical medical_review" href="/z/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Monitoring iron stores'</a> and  <a class="medical medical_review" href="/z/d/html/115637.html" rel="external">"Anemia in pregnancy", section on 'Iron deficiency'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Contraception</span><span class="headingEndMark"> — </span>All individuals should be offered contraception. The choice of method is individualized. (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p>Because of the increased risk of VTE and stroke in females with SCD, combined hormonal contraceptives (with estrogen), which increase the risk of VTE and stroke, should be avoided. Progestin-only contraceptives (except for depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> [DMPA]) are preferred [<a href="#rid96">96</a>]. DMPA, as opposed to other progestin-only contraceptives, has been found to increase the risk of VTE approximately twofold [<a href="#rid96">96</a>].</p><p>The <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">levonorgestrel intrauterine device</a> (IUD) decreases menstrual bleeding and is an excellent contraceptive choice. The <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">copper IUD</a> increases menstrual bleeding, which makes it less desirable in individuals with SCD. (See  <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection"</a>.)</p><p class="headingAnchor" id="H1483728"><span class="h2">Infant care</span><span class="headingEndMark"> — </span>Routine care is appropriate, and breastfeeding is encouraged. (See  <a class="medical medical_review" href="/z/d/html/5068.html" rel="external">"Overview of the routine management of the healthy newborn infant"</a> and <a class="local">'Breastfeeding'</a> above.)</p><p>In addition, the following SCD-specific considerations may apply:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobinopathy testing</strong> – This testing is part of routine newborn care in most of the United States. (See  <a class="medical medical_review" href="/z/d/html/4980.html" rel="external">"Overview of newborn screening"</a>.)</p><p></p><p class="bulletIndent1">In parts of the world where screening for hemoglobinopathy is not routine and paternal testing is not common, the neonate of a mother with SCD should be tested for hemoglobinopathy due to the high prevalence of hemoglobinopathy in offspring. In one study from Ghana, approximately 15 percent of offspring born to mothers with SCD also had SCD [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal opioid use</strong> – If the mother was receiving chronic opioid therapy during pregnancy to reduce vaso-occlusive pain episodes, the neonate should be monitored for neonatal abstinence syndrome. (See  <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">"Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breastfeeding with</strong> <strong>hydroxyurea</strong> – Some individuals may breastfeed while restarting <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> (details to minimize risk are discussed above), some may forego breastfeeding to start hydroxyurea, and some may delay restarting hydroxyurea to allow breastfeeding. (See <a class="local">'Breastfeeding'</a> above and <a class="local">'Restarting medications'</a> above.)</p><p></p><p class="headingAnchor" id="H1124741112"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110843.html" rel="external">"Society guideline links: Sickle cell disease and thalassemias"</a>.)</p><p class="headingAnchor" id="H11336863"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16730.html" rel="external">"Patient education: Sickle cell disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2499068327"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/132604.html" rel="external">"Patient perspective: Sickle cell disease"</a>.)</p><p class="headingAnchor" id="H18580424"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Before conception</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Counseling</strong> – Discuss the likelihood of sickle cell disease (SCD) in a child, reproductive options, possible cord blood banking, plans regarding <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, and the option of genetic counseling. (See <a class="local">'Counseling prior to pregnancy'</a> above and <a class="local">'Likelihood of SCD in offspring and reproductive options'</a> above and <a class="local">'Spontaneous pregnancy loss (miscarriage) and termination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maternal and fetal risks</strong> – Maternal risks include increased vaso-occlusive complications (pain, acute chest syndrome), infections, preeclampsia, and mortality, especially in the third trimester. Fetal risks are increased for preterm birth, low birth weight, intrauterine growth restriction, and perinatal mortality. (See <a class="local">'Maternal risks'</a> above and <a class="local">'Pediatric outcomes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluations</strong> – Evaluations are required to assess iron status and red blood cell (RBC) alloantibodies, prevent infection, and document underlying organ function  (<a class="graphic graphic_table graphicRef140441" href="/z/d/graphic/140441.html" rel="external">table 1</a>). (See <a class="local">'Pre-pregnancy evaluations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medications</strong> – A nuanced discussion should occur regarding whether to continue <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>, timing of discontinuation, and use of transfusions. Iron chelators and other contraindicated medicines are discontinued. Opioids can continue. Appropriate vaccines are administered. Prenatal vitamins can be used, but some individuals should omit iron, and the recommended dose of <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> is higher (4 mg daily) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Vaccines and medication management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>During pregnancy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assessments</strong> – Review baseline health assessments and counseling. Second- and third-trimester assessments include blood pressure; urine protein; fetal screenings (including hemolytic disease of the fetus and newborn (HDFN) in individuals with alloantibodies or a history of alloantibodies); and, in addition to routine prenatal testing, testing for asymptomatic bacteriuria  (<a class="graphic graphic_table graphicRef140441" href="/z/d/graphic/140441.html" rel="external">table 1</a>). We increase ultrasound screening for fetal growth restriction and fetal assessment in the third trimester. (See <a class="local">'Maternal care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complications</strong> – Vaso-occlusive pain prevention involves disease-modifying therapies (<a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a> or transfusions) and avoiding dehydration, hypoxia, acidosis, infection, and cold. Pain is treated promptly and adequately. Nonsteroidal antiinflammatory drugs (NSAIDS) are avoided. Transfusions may be used to treat or prevent complications. (See <a class="local">'Prevention and treatment of acute painful episodes'</a> above and <a class="local">'Management of other complications of SCD'</a> above and <a class="local">'Transfusion therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Labor and delivery</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Delivery </strong>– There are no medical contraindications to vaginal delivery; cesarean birth is reserved for obstetric indications. Induction of labor at 37 to 39 weeks is reasonable (even without maternal or fetal complications), with details individualized to genotype and comorbidities. (See <a class="local">'Vaginal versus cesarean birth'</a> above and <a class="local">'Timing'</a> above.)</p><p></p><p class="bulletIndent2">If time allows, simple transfusion prior to cesarean birth is reasonable in patients at increased risk of complications. Continuous fetal heart rate monitoring is appropriate. The patient should be kept warm, hydrated, and well oxygenated. Umbilical cord blood can be used for newborn screening and harvested for hematopoietic stem cell transplant if desired. (See <a class="local">'Monitoring and supportive care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Venous thromboembolism (VTE) prophylaxis</strong> – After cesarean or vaginal delivery, we suggest prophylactic dose low molecular weight (LMW) heparin rather than no VTE prophylaxis (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'VTE prophylaxis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Breastfeeding and medications</strong> – Breastfeeding should be encouraged and is possible in individuals taking <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>. If hydroxyurea was restarted, it may take up to six months for full therapeutic effect. Iron status should be evaluated before restarting chelation. (See <a class="local">'Breastfeeding'</a> above and <a class="local">'Restarting medications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraception</strong> – Contraception should be discussed. Progestin-only contraceptives or nonhormonal methods are preferred. Estrogen-containing contraceptives and depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA) increase the risk of VTE and generally are not the best choice. The <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">levonorgestrel intrauterine device</a> (IUD) decreases menstrual bleeding and is an excellent contraceptive; the <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">copper IUD</a> increases bleeding, making it less desirable in individuals with SCD. (See <a class="local">'Contraception'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infant </strong>– Hemoglobinopathy testing is routine in some countries; if not, it should be performed. If the mother was receiving chronic opioid therapy, the neonate should be monitored for opioid withdrawal. (See <a class="local">'Infant care'</a> above.)</p><p></p><p class="headingAnchor" id="H2946872948"><span class="h1">ACKNOWLEDGMENTS</span></p><p>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The UpToDate editorial staff also acknowledges Elliott P Vichinsky, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">de Montalembert M, Deneux-Tharaux C. Pregnancy in sickle cell disease is at very high risk. Blood 2015; 125:3216.</a></li><li><a class="nounderline abstract_t">Oppong SA, Asare EV, Olayemi E, et al. Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting. Am J Hematol 2019; 94:223.</a></li><li><a class="nounderline abstract_t">Asare EV, Olayemi E, Boafor T, et al. Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting. Am J Hematol 2017; 92:872.</a></li><li><a class="nounderline abstract_t">Schultz CL, Tchume-Johnson T, Jackson T, et al. Reproductive intentions in mothers of young children with sickle cell disease. Pediatr Blood Cancer 2020; 67:e28227.</a></li><li><a class="nounderline abstract_t">K Piper, M McLemore, F El Rassi, et al. Unintended Pregnancy Among People with Sickle Cell Disease or Sickle Cell Trait [5S]. Obstet Gynecol 2019; 133:203S.</a></li><li class="breakAll">http://www.nhlbi.nih.gov/health-pro/guidelines/current/management-sickle-cell-disease.htm (Accessed on September 30, 2014).</li><li><a class="nounderline abstract_t">Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.</a></li><li><a class="nounderline abstract_t">Anie KA, Treadwell MJ, Grant AM, et al. Community engagement to inform the development of a sickle cell counselor training and certification program in Ghana. J Community Genet 2016; 7:195.</a></li><li><a class="nounderline abstract_t">Oteng-Ntim E, Meeks D, Seed PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood 2015; 125:3316.</a></li><li><a class="nounderline abstract_t">Boafor TK, Olayemi E, Galadanci N, et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG 2016; 123:691.</a></li><li><a class="nounderline abstract_t">Powars DR, Sandhu M, Niland-Weiss J, et al. Pregnancy in sickle cell disease. Obstet Gynecol 1986; 67:217.</a></li><li><a class="nounderline abstract_t">Adams S. Caring for the pregnant woman with sickle cell crisis. Prof Care Mother Child 1996; 6:34.</a></li><li><a class="nounderline abstract_t">Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol 2003; 120:744.</a></li><li><a class="nounderline abstract_t">Martin JN Jr, Martin RW, Morrison JC. Acute management of sickle cell crisis in pregnancy. Clin Perinatol 1986; 13:853.</a></li><li><a class="nounderline abstract_t">Al Jama FE, Gasem T, Burshaid S, et al. Pregnancy outcome in patients with homozygous sickle cell disease in a university hospital, Eastern Saudi Arabia. Arch Gynecol Obstet 2009; 280:793.</a></li><li><a class="nounderline abstract_t">Rajab KE, Issa AA, Mohammed AM, Ajami AA. Sickle cell disease and pregnancy in Bahrain. Int J Gynaecol Obstet 2006; 93:171.</a></li><li><a class="nounderline abstract_t">Ngô C, Kayem G, Habibi A, et al. Pregnancy in sickle cell disease: maternal and fetal outcomes in a population receiving prophylactic partial exchange transfusions. Eur J Obstet Gynecol Reprod Biol 2010; 152:138.</a></li><li><a class="nounderline abstract_t">Al Kahtani MA, AlQahtani M, Alshebaily MM, et al. Morbidity and pregnancy outcomes associated with sickle cell anemia among Saudi women. Int J Gynaecol Obstet 2012; 119:224.</a></li><li><a class="nounderline abstract_t">Asare EV, Olayemi E, Boafor T, et al. Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD. Am J Hematol 2019; 94:E328.</a></li><li><a class="nounderline abstract_t">Cardosa D, Ridout A, Nanda S, et al. Maternal sickle cell disease and twin pregnancy: a case series and review of the literature. Hematology 2019; 24:148.</a></li><li><a class="nounderline abstract_t">Agarwal S, Stanek JR, Vesely SK, et al. Pregnancy-related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data. Am J Hematol 2023; 98:1677.</a></li><li><a class="nounderline abstract_t">Villers MS, Jamison MG, De Castro LM, James AH. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008; 199:125.e1.</a></li><li><a class="nounderline abstract_t">Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.</a></li><li><a class="nounderline abstract_t">Koshy M, Chisum D, Burd L, et al. Management of sickle cell anemia and pregnancy. J Clin Apher 1991; 6:230.</a></li><li class="breakAll">Maternal mortality ratio (modeled estimate, per 100,000 live births)
WHO, UNICEF, UNFPA, World Bank Group, and the United Nations Population Division. Trends in Maternal Mortality: 2000 to 2017. Geneva, World Health Organization, 2019. https://data.worldbank.org/indicator/SH.STA.MMRT (Accessed on April 15, 2020).</li><li><a class="nounderline abstract_t">Early ML, Eke AC, Gemmill A, et al. Severe Maternal Morbidity and Mortality in Sickle Cell Disease in the National Inpatient Sample, 2012-2018. JAMA Netw Open 2023; 6:e2254552.</a></li><li><a class="nounderline abstract_t">Hassell K. Pregnancy and sickle cell disease. Hematol Oncol Clin North Am 2005; 19:903.</a></li><li><a class="nounderline abstract_t">Asnani MR, McCaw-Binns AM, Reid ME. Excess risk of maternal death from sickle cell disease in Jamaica: 1998-2007. PLoS One 2011; 6:e26281.</a></li><li><a class="nounderline abstract_t">Rogers DT, Molokie R. Sickle cell disease in pregnancy. Obstet Gynecol Clin North Am 2010; 37:223.</a></li><li><a class="nounderline abstract_t">Asare EV, Olayemi E, Boafor T, et al. A case series describing causes of death in pregnant women with sickle cell disease in a low-resource setting. Am J Hematol 2018; 93:E167.</a></li><li><a class="nounderline abstract_t">Milner PF, Jones BR, Döbler J. Outcome of pregnancy in sickle cell anemia and sickle cell-hemoglobin C disease. An analysis of 181 pregnancies in 98 patients, and a review of the literature. Am J Obstet Gynecol 1980; 138:239.</a></li><li><a class="nounderline abstract_t">Serjeant GR, Hambleton I, Thame M. Fecundity and pregnancy outcome in a cohort with sickle cell-haemoglobin C disease followed from birth. BJOG 2005; 112:1308.</a></li><li><a class="nounderline abstract_t">Oteng-Ntim E, Ayensah B, Knight M, Howard J. Pregnancy outcome in patients with sickle cell disease in the UK--a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. Br J Haematol 2015; 169:129.</a></li><li><a class="nounderline abstract_t">Morris RK, Riley RD, Doug M, et al. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ 2012; 345:e4342.</a></li><li><a class="nounderline abstract_t">Kassim AA, Payne AB, Rodeghier M, et al. Low forced expiratory volume is associated with earlier death in sickle cell anemia. Blood 2015; 126:1544.</a></li><li><a class="nounderline abstract_t">Inparaj S, Buckingham M, Oakley L, et al. Pulmonary complications for women with sickle cell disease in pregnancy: systematic review and meta-analysis. Thorax 2020; 75:568.</a></li><li><a class="nounderline abstract_t">Hayfron-Benjamin CF, Asare EV, Boafor T, et al. Low FEV1 is associated with fetal death in pregnant women with sickle cell disease. Am J Hematol 2021; 96:E303.</a></li><li><a class="nounderline abstract_t">Pham BN, Peyrard T, Juszczak G, et al. Analysis of RhCE variants among 806 individuals in France: considerations for transfusion safety, with emphasis on patients with sickle cell disease. Transfusion 2011; 51:1249.</a></li><li><a class="nounderline abstract_t">Chou ST, Jackson T, Vege S, et al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122:1062.</a></li><li><a class="nounderline abstract_t">Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology Am Soc Hematol Educ Program 2013; 2013:439.</a></li><li><a class="nounderline abstract_t">Reid ME, Halter Hipsky C, Hue-Roye K, Hoppe C. Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease. Blood Cells Mol Dis 2014; 52:195.</a></li><li><a class="nounderline abstract_t">Westhoff CM. Blood group genotyping. Blood 2019; 133:1814.</a></li><li class="breakAll">NHLBI. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. p.24. http://www.nhlbi.nih.gov/guidelines (Accessed on August 11, 2014).</li><li class="breakAll">Hemoglobinopathies in Pregnancy. American College of Obstetricians and Gynecologists. Available at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/08/hemoglobinopathies-in-pregnancy (Accessed on October 13, 2022).</li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists' Presidential Task Force on Pregnancy and Heart Disease and Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 212: Pregnancy and Heart Disease. Obstet Gynecol 2019; 133:e320.</a></li><li><a class="nounderline abstract_t">Kroner BL, Hankins JS, Pugh N, et al. Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. Am J Hematol 2022; 97:603.</a></li><li><a class="nounderline abstract_t">de Montalembert M, Voskaridou E, Oevermann L, et al. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am J Hematol 2021; 96:1223.</a></li><li><a class="nounderline abstract_t">Campion SN, Davenport SJ, Nowland WS, et al. Sensitive windows of skeletal development in rabbits determined by hydroxyurea exposure at different times throughout gestation. Birth Defects Res B Dev Reprod Toxicol 2012; 95:238.</a></li><li><a class="nounderline abstract_t">Wise LD, Winkelmann CT. Evaluation of hydroxyurea-induced fetal skeletal changes in Dutch belted rabbits by micro-computed tomography and alizarin red staining. Birth Defects Res B Dev Reprod Toxicol 2009; 86:220.</a></li><li><a class="nounderline abstract_t">Woo GH, Katayama K, Bak EJ, et al. Effects of prenatal hydroxyurea-treatment on mouse offspring. Exp Toxicol Pathol 2004; 56:1.</a></li><li><a class="nounderline abstract_t">Aliverti V, Bonanomi L, Giavini E. Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats. Arch Toxicol Suppl 1980; 4:239.</a></li><li><a class="nounderline abstract_t">Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J 2007; 37:190.</a></li><li><a class="nounderline abstract_t">Masood J, Hafeez A, Hughes A, Barua JM. Hydroxyurea therapy: a rare cause of reversible azoospermia. Int Urol Nephrol 2007; 39:905.</a></li><li><a class="nounderline abstract_t">Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008; 93:988.</a></li><li><a class="nounderline abstract_t">DeBaun MR. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review. Expert Rev Hematol 2014; 7:767.</a></li><li><a class="nounderline abstract_t">Berthaut I, Bachir D, Kotti S, et al. Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment. Blood 2017; 130:2354.</a></li><li><a class="nounderline abstract_t">Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev 2022; 9:CD002202.</a></li><li class="breakAll">: https://ashpublications.org/ashclinicalnews/news/6501/You-Make-the-Call-What-would-you-advise-for-a-male?searchresult=1 (Accessed on May 02, 2023).</li><li class="breakAll">Pregnancy, contraception and fertility. In: Standards for the Clinical Care of Adults with Sickle Cell Disease in the UK, 2008. p.59.</li><li><a class="nounderline abstract_t">ACOG Committee on Obstetrics. ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy. Obstet Gynecol 2007; 109:229. Reaffirmed 2018. Reaffirmed 2020.</a></li><li class="breakAll">Oppong S A, Stewart J-A, DeBaun MR. Management of Sickle cell disease in pregnancy. In: Sickle Cell Disease, Mark T Gladwin, Gregory J Kato, Enrich M Novelli (Eds), McGraw Hill, 2021. p.195.</li><li><a class="nounderline abstract_t">Taher AT, Iolascon A, Matar CF, et al. Recommendations for Pregnancy in Rare Inherited Anemias. Hemasphere 2020; 4:e446.</a></li><li class="breakAll">Doxycycline. www.reprotox.org (Accessed on March 04, 2021).</li><li class="breakAll">Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 8th edition, Lippincott Williams &amp; Wilkins.</li><li><a class="nounderline abstract_t">Singer ST, Vichinsky EP. Deferoxamine treatment during pregnancy: is it harmful? Am J Hematol 1999; 60:24.</a></li><li><a class="nounderline abstract_t">Pintova S, Cohen HW, Billett HH. Sickle cell trait: is there an increased VTE risk in pregnancy and the postpartum? PLoS One 2013; 8:e64141.</a></li><li><a class="nounderline abstract_t">Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007; 110:908.</a></li><li><a class="nounderline abstract_t">Noubiap JJ, Temgoua MN, Tankeu R, et al. Sickle cell disease, sickle trait and the risk for venous thromboembolism: a systematic review and meta-analysis. Thromb J 2018; 16:27.</a></li><li><a class="nounderline abstract_t">Rahimy MC, Gangbo A, Adjou R, et al. Effect of active prenatal management on pregnancy outcome in sickle cell disease in an African setting. Blood 2000; 96:1685.</a></li><li><a class="nounderline abstract_t">Asare EV, DeBaun MR, Olayemi E, et al. Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy. Hematology Am Soc Hematol Educ Program 2022; 2022:388.</a></li><li class="breakAll">Oppong SA, Stewart JA, DeBaun MR. Management of sickle cell disease in pregnancy. In: Sickle Cell Disease, Gladwin MT, Kato GJ, Novelli EM (Eds), McGraw Hill, 2021. p.195.</li><li><a class="nounderline abstract_t">Rathod KB, Jaiswal KN, Shrivastava AC, Shrikhande AV. Study of placenta in sickle cell disorders. Indian J Pathol Microbiol 2007; 50:698.</a></li><li><a class="nounderline abstract_t">Howard J, Oteng-Ntim E. The obstetric management of sickle cell disease. Best Pract Res Clin Obstet Gynaecol 2012; 26:25.</a></li><li><a class="nounderline abstract_t">Abudu OO, Macaulay K, Oluboyede OA. Serial evaluation of iron stores in pregnant Nigerians with hemoglobin SS or SC. J Natl Med Assoc 1990; 82:41.</a></li><li><a class="nounderline abstract_t">Okusanya BO, Oladapo OT. Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database Syst Rev 2013; :CD010378.</a></li><li><a class="nounderline abstract_t">Aghamolaei T, Pormehr-Yabandeh A, Hosseini Z, et al. Pregnancy in the Sickle Cell Disease and Fetomaternal Outcomes in Different Sickle cell Genotypes: A Systematic Review and Meta-Analysis. Ethiop J Health Sci 2022; 32:849.</a></li><li><a class="nounderline abstract_t">Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369:1791.</a></li><li><a class="nounderline abstract_t">Ribeil JA, Labopin M, Stanislas A, et al. Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory. Am J Hematol 2018; 93:794.</a></li><li><a class="nounderline abstract_t">Barrett AN, McDonnell TC, Chan KC, Chitty LS. Digital PCR analysis of maternal plasma for noninvasive detection of sickle cell anemia. Clin Chem 2012; 58:1026.</a></li><li><a class="nounderline abstract_t">Phylipsen M, Yamsri S, Treffers EE, et al. Non-invasive prenatal diagnosis of beta-thalassemia and sickle-cell disease using pyrophosphorolysis-activated polymerization and melting curve analysis. Prenat Diagn 2012; 32:578.</a></li><li><a class="nounderline abstract_t">van Campen J, Silcock L, Yau S, et al. A novel non-invasive prenatal sickle cell disease test for all at-risk pregnancies. Br J Haematol 2020; 190:119.</a></li><li><a class="nounderline abstract_t">Santana DS, Cecatti JG, Parpinelli MA, et al. Severe maternal morbidity due to abortion prospectively identified in a surveillance network in Brazil. Int J Gynaecol Obstet 2012; 119:44.</a></li><li><a class="nounderline abstract_t">Zhang J, Gilles JM, Barnhart K, et al. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med 2005; 353:761.</a></li><li><a class="nounderline abstract_t">Martí-Carvajal AJ, Peña-Martí GE, Comunián-Carrasco G, Martí-Peña AJ. Interventions for treating painful sickle cell crisis during pregnancy. Cochrane Database Syst Rev 2009; :CD006786.</a></li><li><a class="nounderline abstract_t">Winder AD, Johnson S, Murphy J, Ehsanipoor RM. Epidural analgesia for treatment of a sickle cell crisis during pregnancy. Obstet Gynecol 2011; 118:495.</a></li><li><a class="nounderline abstract_t">Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020; 4:327.</a></li><li><a class="nounderline abstract_t">Koshy M, Burd L, Wallace D, et al. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med 1988; 319:1447.</a></li><li><a class="nounderline abstract_t">Malinowski AK, Shehata N, D'Souza R, et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood 2015; 126:2424.</a></li><li><a class="nounderline abstract_t">Grobman WA, Rice MM, Reddy UM, et al. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. N Engl J Med 2018; 379:513.</a></li><li><a class="nounderline abstract_t">Fashakin V, Weber JM, Truong T, et al. Sickle cell disease and the incidence and etiology of preterm birth. Am J Obstet Gynecol MFM 2022; 4:100723.</a></li><li><a class="nounderline abstract_t">Voskaridou E, Christoulas D, Terpos E. Sickle-cell disease and the heart: review of the current literature. Br J Haematol 2012; 157:664.</a></li><li><a class="nounderline abstract_t">Rizk S, Pulte ED, Axelrod D, Ballas SK. Perinatal Maternal Mortality in Sickle Cell Anemia: Two Case Reports and Review of the Literature. Hemoglobin 2017; 41:225.</a></li><li><a class="nounderline abstract_t">Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2:3317.</a></li><li class="breakAll">Practice Bulletin: Thromboembolism in Pregnancy. The American College of Obstetricians and Gynecologists. Available at: https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2018/07/thromboembolism-in-pregnancy (Accessed on March 28, 2023).</li><li><a class="nounderline abstract_t">Ware RE, Marahatta A, Ware JL, et al. Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). J Pediatr 2020; 222:236.</a></li><li><a class="nounderline abstract_t">Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception 2016; 94:678.</a></li></ol></div><div id="topicVersionRevision">Topic 7139 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999441" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pregnancy in sickle cell disease is at very high risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30456766" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28512745" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32065500" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Reproductive intentions in mothers of young children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Unintended Pregnancy Among People with Sickle Cell Disease or Sickle Cell Trait [5S]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Unintended Pregnancy Among People with Sickle Cell Disease or Sickle Cell Trait [5S]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203083" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27090687" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Community engagement to inform the development of a sickle cell counselor training and certification program in Ghana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25800049" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26667608" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3945432" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pregnancy in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704414" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Caring for the pregnant woman with sickle cell crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614204" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Guidelines for the management of the acute painful crisis in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3539455" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acute management of sickle cell crisis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19271230" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pregnancy outcome in patients with homozygous sickle cell disease in a university hospital, Eastern Saudi Arabia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16563397" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sickle cell disease and pregnancy in Bahrain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846778" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pregnancy in sickle cell disease: maternal and fetal outcomes in a population receiving prophylactic partial exchange transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22986097" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Morbidity and pregnancy outcomes associated with sickle cell anemia among Saudi women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31571271" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345909" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Maternal sickle cell disease and twin pregnancy: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37551881" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pregnancy-related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18533123" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Morbidity associated with sickle cell disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315276" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1816245" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management of sickle cell anemia and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1816245" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Management of sickle cell anemia and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36729452" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Severe Maternal Morbidity and Mortality in Sickle Cell Disease in the National Inpatient Sample, 2012-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214651" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pregnancy and sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039456" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Excess risk of maternal death from sickle cell disease in Jamaica: 1998-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20685550" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sickle cell disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29659044" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A case series describing causes of death in pregnant women with sickle cell disease in a low-resource setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7416213" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Outcome of pregnancy in sickle cell anemia and sickle cell-hemoglobin C disease. An analysis of 181 pregnancies in 98 patients, and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16101613" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fecundity and pregnancy outcome in a cohort with sickle cell-haemoglobin C disease followed from birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25522142" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pregnancy outcome in patients with sickle cell disease in the UK--a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22777026" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261241" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Low forced expiratory volume is associated with earlier death in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32345690" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pulmonary complications for women with sickle cell disease in pregnancy: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33984165" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Low FEV1 is associated with fetal death in pregnant women with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21166680" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Analysis of RhCE variants among 806 individuals in France: considerations for transfusion safety, with emphasis on patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23723452" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24319217" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transfusion therapy for sickle cell disease: a balancing act.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309423" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30808639" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Blood group genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30808639" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Blood group genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30808639" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Blood group genotyping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31022123" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : ACOG Practice Bulletin No. 212: Pregnancy and Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35142007" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34224583" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22495808" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sensitive windows of skeletal development in rabbits determined by hydroxyurea exposure at different times throughout gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19479798" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evaluation of hydroxyurea-induced fetal skeletal changes in Dutch belted rabbits by micro-computed tomography and alizarin red staining.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15581269" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effects of prenatal hydroxyurea-treatment on mouse offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6933910" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17316339" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17333529" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hydroxyurea therapy: a rare cause of reversible azoospermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18508803" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25242414" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972009" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36047926" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hydroxyurea (hydroxycarbamide) for sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36047926" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hydroxyurea (hydroxycarbamide) for sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36047926" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hydroxyurea (hydroxycarbamide) for sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17197616" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17197616" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32885142" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Recommendations for Pregnancy in Rare Inherited Anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32885142" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recommendations for Pregnancy in Rare Inherited Anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32885142" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Recommendations for Pregnancy in Rare Inherited Anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9883802" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Deferoxamine treatment during pregnancy: is it harmful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23717554" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sickle cell trait: is there an increased VTE risk in pregnancy and the postpartum?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17409269" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sickle cell trait and the risk of venous thromboembolism among blacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30305805" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sickle cell disease, sickle trait and the risk for venous thromboembolism: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10961864" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of active prenatal management on pregnancy outcome in sickle cell disease in an African setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36485167" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36485167" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18306531" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Study of placenta in sickle cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22113135" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The obstetric management of sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2304096" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Serial evaluation of iron stores in pregnant Nigerians with hemoglobin SS or SC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297507" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35950054" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pregnancy in the Sickle Cell Disease and Fetomaternal Outcomes in Different Sickle cell Genotypes: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17512048" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29603363" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by the international sickle cell disease observatory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22451622" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Digital PCR analysis of maternal plasma for noninvasive detection of sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517437" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Non-invasive prenatal diagnosis of beta-thalassemia and sickle-cell disease using pyrophosphorolysis-activated polymerization and melting curve analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32097993" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A novel non-invasive prenatal sickle cell disease test for all at-risk pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22819315" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Severe maternal morbidity due to abortion prospectively identified in a surveillance network in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120856" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A comparison of medical management with misoprostol and surgical management for early pregnancy failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160301" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Interventions for treating painful sickle cell crisis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768865" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Epidural analgesia for treatment of a sickle cell crisis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31985807" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3054555" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26302758" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30089070" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Labor Induction versus Expectant Management in Low-Risk Nulliparous Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35995364" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Sickle cell disease and the incidence and etiology of preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22530942" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Sickle-cell disease and the heart: review of the current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182088" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Perinatal Maternal Mortality in Sickle Cell Anemia: Two Case Reports and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482767" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482767" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171562" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27153743" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Progestin-only contraception and thromboembolism: A systematic review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
